Drugs / 89Zr-DFO-cRGDY-PEG-Cy5-C' dots
89Zr-DFO-cRGDY-PEG-Cy5-C' dots
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03465618 | Mar 2018 → Mar 2027 expected | brain cancer, pituitary gland adenoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-DFO-cRGDY-PEG-Cy5-C' dots | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03465618 ↗ |
| Modality | Diagnostic / imaging agent | “PET scans using 89Zr-DFO-cRGDY-PEG-Cy5-C' dot particles” NCT03465618 ↗ |
| Route | Intravenous | “i.v. injected” NCT03465618 ↗ |